Cat. No. 3400
Chemical Name: (bis(2,2'-Bipyridine-N,N')triphenylph
Biological ActivityRuthenium-bipyridine-triphenylphosphine caged GABA (Cat. No. 0344) that is excited by visible wavelengths. Provides greater tissue penetration, less phototoxicity, faster photorelease kinetics and better spatial resolution than UV light-sensitive caged compounds. Produces GABA receptor-mediated currents in pyramidal neurons in vitro and displays no effect on endogenous GABAergic or glutamatergic transmission at concentrations effective for uncaging.
Licensing InformationSold under licence from Columbia University
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Rial Verde et al (2008) Photorelease of GABA with visible light using an inorganic caging group. Front.Neural Circuits 2 2. PMID: 18946542.
Zayat et al (2003) A new strategy for neurochemical photodelivery: Metal-ligand heterolytic cleavage. J.Am.Chem.Soc. 125 882. PMID: 12537482.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses RuBi-GABA from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: RuBi-GABA, supplier, Caged, GABA, GABAA, GABAC, Receptors, GABAB, Tocris Bioscience, GABAB Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
FFA2 antagonist/inverse agonistOleanolic acid
Selective GPBA receptor (TGR5) partial agonistPPTN hydrochloride
High affinity and selective P2Y14 antagonistItraconazole
SMO antagonist; acts at different binding site to cyclopamine (Cat No. 1623)SAR 216471 hydrochloride
Potent P2Y12 antagonist; orally availableA 971432
Potent and selective S1P5 agonistGLPG 0974
Potent FFA2 antagonistOgerin
Selective positive allosteric modulator at GPR68BGC 20-1531 hydrochloride
High affinity and selective EP4 antagonistMontelukast sodium
CysLT1 and GPR17 antagonist
October 30 - November 3, 2016
Boston, MA, USA